Two-year update from KEYNOTE-799: Pembrolizumab plus concurrent chemoradiation therapy (cCRT) for unresectable, locally advanced, stage III NSCLC.

被引：0

作者：

Reck, Martin

Lee, Ki Hyeong

Frost, Nicolaj

Breder, Valeriy Vladimirovich

Kowalski, Dariusz

Levchenko, Evgeny

Reguart, Noemi

Martinez-Marti, Alex

Houghton, Baerin

Paoli, Jean-Baptiste

Safina, Sufiia

Komiya, Takefumi

Sanford, Amy

Liu, Hong

Song, Andrew J.

Keller, Steven M.

Jabbour, Salma K.

机构：

[1] Airway Res Ctr North, German Ctr Lung Res, LungenClin, Grosshansdorf, Germany

[2] Chungbuk Natl Univ, Chungbuk Natl Univ Hosp, Coll Med, Cheongju, South Korea

[3] Charit Univ Berlin, Dept Infect Dis & Resp Med, Berlin, Germany

[4] Free Univ Berlin, Berlin, Germany

[5] Humboldt Univ, Berlin, Germany

[6] Berlin Inst Hlth, Berlin, Germany

[7] N N Blokhin Russian Canc Res Ctr, Moscow, Russia

[8] Maria Sklodowska Curie Natl Res Inst Oncol, Warsaw, Poland

[9] N N Petrov Natl Med Res Ctr Oncol, St Petersburg, Russia

[10] Hosp Clin Barcelona, Dept Med Oncol, Thorac Oncol Unit, IDIBAPS, Barcelona, Spain

[11] Vall Hebron Inst Oncol VHIO, Hosp Univ Vall Hebron, Barcelona, Spain

[12] Mid North Coast Canc Inst, Port Macquarie Base Hosp, Port Macquarie, NSW, Australia

[13] Clin Clairval, Radiotherapie, Marseille, France

[14] Republican Dispensary Tatarstan MoH, Med Oncol, Kazan, Russia

[15] Sunny Buffalo, Div Hematol Oncol, Buffalo, NY USA

[16] Sanford Hlth, Sioux Falls, SD USA

[17] Merck Co Inc, Kenilworth, NJ USA

[18] Rutgers State Univ, Rutgers Canc Inst New Jersey, Robert Wood Johnson Med Sch, Dept Radiat Oncol, New Brunswick, NJ USA

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2022年 / 40卷 / 16期

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

8508

引用

页数：1

共 35 条

[21] RATIONALE 001: Tislelizumab (BGB-A317) 1 concurrent chemoradiotherapy (cCRT) followed by tislelizumab monotherapy in patients (pts) with newly diagnosed locally advanced, unresectable, stage III non-small cell lung cancer (NSCLC)
Paz-Ares, L.
Senan, S.
Planchard, D.
Wang, L.
Cheong, A.
Slepetis, R.
Nguyen, M. H.
Vokes, E. E.
ANNALS OF ONCOLOGY, 2019, 30 : 67 - 67
[22] CheckMate 73L: A phase III study comparing nivolumab (NIVO) plus concurrent chemoradiotherapy (CCRT) followed by NIVO ± ipilimumab (IPI) versus CCRT followed by durvalumab (DURV) for previously untreated, locally advanced (LA) stage III non-small cell lung cancer (NSCLC)
De Ruysscher, D.
Ramalingam, S. S.
Urbanic, J.
Gerber, D. E.
Tan, D. S. W.
Cai, J.
Li, A.
Peters, S.
ANNALS OF ONCOLOGY, 2020, 31 : S810 - S810
[23] Radiation therapy (RT) quality control (QC) in a French multicentric randomised phase II trial -glot Gfpc Ifct 02.01-including concurrent chemoradiation (CCRT) for unresectable stage III non-small-cell lung cancer (NSCLC)
Martel-Lafay, I.
Clavere, P.
Labat, J.
Benchalal, M.
Talabard, J.
Teissier, E.
d'Hombres, A.
Touboul, E.
Vergnenegre, A.
Fournel, P.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2006, 66 (03): : S149 - S149
[24] A PHASE 3, RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED, INTERNATIONAL STUDY OF MEDI4736 IN PATIENTS WITH LOCALLY ADVANCED, UNRESECTABLE NSCLC (STAGE III) WHO HAVE NOT PROGRESSED FOLLOWING PLATINUM-BASED, CONCURRENT CHEMORADIATION THERAPY (PACIFIC)
Antonia, S.
Iannotti, N. O.
Salamat, M. A.
Krebs, A. D.
Jayawardene, D.
Ballas, M.
Stockman, P. K.
ANNALS OF ONCOLOGY, 2014, 25
[25] Phase II trial of consolidation Pembrolizumab following concurrent chemoradiation in patients (pts) with unresectable or inoperable stage III non-small cell lung cancer (NSCLC): initial safety data from HCRN LUN 14-179.
Durm, Greg Andrew
Kio, Ebenezer A.
Fisher, William B.
Titzer, Michael L.
Jabbour, Salma
Tim, Breen
Liu, Ziyue
Hanna, Nasser H.
JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
[26] SWOG 0023: A randomized phase III trial of cisplatin/etoposide (PE) plus radiation therapy followed by consolidation docetaxel then maintenance therapy with gefitinib or placebo in patients with locally advanced unresectable stage III non-small cell lung cancer (NSCLC)
Kelly, K
Gaspar, LE
Chanksy, K
Albain, KS
Jett, J
Ung, Y
Crowley, JJ
Gandara, DR
LUNG CANCER, 2005, 49 : S64 - S64
[27] Concurrent chemoradiation (CChRT) for locally advanced stage III non-small cell lung cancer (NSCLC) with cisplatin and vinorelbine and thoracic radiotherapy: A phase II study from the Galician Lung Cancer Group.
Garcia, Susana Gomez
Rivas, Marinha Costa
Manrique, Ma Carmen Areses
Nunez, Natalia Fernandez
Garcia, Jorge
Caeiro, Manuel
Castro, Enrrique
Formoso, Ines
Calvo, P.
Alvarez, Noemi De Dios
Firvida, J. I.
Campos, Begona
Azpitarte, Cristina
Javier, Francisco
JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
[28] A PHASE 3, RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED, INTERNATIONAL STUDY OF MEDI4736 IN PATIENTS WITH LOCALLY ADVANCED, UNRESECTABLE, STAGE 3 NSCLC WHO HAVE NOT PROGRESSED FOLLOWING PLATINUM-BASED, CONCURRENT CHEMORADIATION THERAPY (PACIFIC)
Creelan, B.
Iannotti, N. O.
Salamat, M. A.
Jayawardene, D.
Ballas, M.
Stockman, P. K.
Antonia, S. J.
ANNALS OF ONCOLOGY, 2015, 26
[29] Initial Cooperative Group Experience of Bevacizumab (Bev) Plus Concomitant Chemoradiation Therapy (CRT) in Patients With Inoperable Locally Advanced Stage III Non-small Cell Lung Cancer (LA-NSCLC): Preliminary Results of 50533
Thomas, C. R.
Moon, J.
Gaspar, L. E.
Raben, D.
Fitzgerald, T. J.
Wozniak, A. J.
Kelly, K.
Mack, P. C.
Pandya, K. J.
Gandara, D. R.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2012, 84 (03): : S156 - S156
[30] GEMSTONE-301: a phase III clinical trial of CS1001 as consolidation therapy in patients with locally advanced/unresectable (stage III) non-small cell lung cancer (NSCLC) who did not have disease progression after prior concurrent/sequential chemoradiotherapy
Zhou, Qing
Chen, Ming
Wu, Gang
Chang, Jian-Hua
Jiang, Ou
Cui, Jiu-Wei
Han, Guang
Lin, Qin
Fang, Jian
Chen, Gong-Yan
Wu, Yi-Long
TRANSLATIONAL LUNG CANCER RESEARCH, 2020, 9 (05) : 2008 - 2015

← 1 2 3 4 →